<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Revexa]]></title><description><![CDATA[Revexa | Research Peptides]]></description><link>https://www.revexa.co.uk/blog</link><generator>RSS for Node</generator><lastBuildDate>Mon, 03 Aug 2026 00:35:00 GMT</lastBuildDate><atom:link href="https://www.revexa.co.uk/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[MOTS-c: the mitochondrial-derived peptide in recent research]]></title><description><![CDATA[Research summary. Everything below describes published research on MOTS-c as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. MOTS-c is unusual, it is a peptide your own mitochondria encode, and it sits at the centre of metabolic and mitochondrial research. It works largely through AMPK, the same cellular energy pathway that exercise activates, which is why it is...]]></description><link>https://www.revexa.co.uk/post/mots-c-the-mitochondrial-derived-peptide-in-recent-research</link><guid isPermaLink="false">6a6fbd763e0c16484ff9e7db</guid><pubDate>Sun, 02 Aug 2026 21:58:14 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[GHK-Cu: the copper peptide in recent skin-repair research]]></title><description><![CDATA[Research summary. Everything below describes published research on GHK-Cu (copper tripeptide-1) as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. GHK-Cu, the copper tripeptide, is one of the most-studied compounds in skin and tissue-repair research, and materials scientists keep finding new ways to work with it. A 2026 study is a good example. A smart hydrogel...]]></description><link>https://www.revexa.co.uk/post/ghk-cu-the-copper-peptide-in-recent-skin-repair-research</link><guid isPermaLink="false">6a6fbd75bca6fdcb434e32c2</guid><pubDate>Sun, 02 Aug 2026 21:58:13 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[BPC-157 and TB-500: the repair-research pair in recent studies]]></title><description><![CDATA[Research summary. Everything below describes published research on BPC-157 and TB-500 (thymosin beta-4) as compounds. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. BPC-157 and TB-500 are the two peptides that dominate tissue-repair research, which is why they are so often studied and discussed together. Two 2026 animal studies looked at them separately. BPC-157 and...]]></description><link>https://www.revexa.co.uk/post/bpc-157-and-tb-500-the-repair-research-pair-in-recent-studies</link><guid isPermaLink="false">6a6fbd74bca6fdcb434e32bd</guid><pubDate>Sun, 02 Aug 2026 21:58:13 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[SS-31 (Elamipretide): the mitochondria-targeting peptide in recent studies]]></title><description><![CDATA[Research summary. Everything below describes published research on SS-31 (elamipretide) as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. SS-31, also known as elamipretide, is a mitochondria-targeting research peptide. It concentrates at the inner mitochondrial membrane, which is why it appears so often in cellular-ageing and mitochondrial-function research. Two...]]></description><link>https://www.revexa.co.uk/post/ss-31-elamipretide-the-mitochondria-targeting-peptide-in-recent-studies</link><guid isPermaLink="false">6a6fbd73bca6fdcb434e32b8</guid><pubDate>Sun, 02 Aug 2026 21:58:12 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[FDA advisory panel votes to back four research peptides]]></title><description><![CDATA[News summary. This describes a regulatory news event, reported from primary sources. It is not advice, and nothing here implies approval, a change in legal status, or any use in people. Products are supplied for laboratory research use only, not for human consumption. On 23 July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding several research peptides to the 503A bulk drug substances list, a move reported to override written objections from the agency's own...]]></description><link>https://www.revexa.co.uk/post/fda-advisory-panel-votes-to-back-four-research-peptides</link><guid isPermaLink="false">6a6fbd733e0c16484ff9e7d0</guid><pubDate>Sun, 02 Aug 2026 21:58:11 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[Retatrutide research: the triple agonist under the microscope]]></title><description><![CDATA[Research summary. Everything below describes published research on retatrutide as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. Retatrutide is the compound the metabolic research world is watching most closely, because of what it does at the receptor level. Where tirzepatide is a dual agonist, retatrutide is a triple agonist, engaging the GLP-1, GIP and glucagon...]]></description><link>https://www.revexa.co.uk/post/retatrutide-research-the-triple-agonist-under-the-microscope</link><guid isPermaLink="false">6a6fbd72bca6fdcb434e32b5</guid><pubDate>Sun, 02 Aug 2026 21:58:10 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item><item><title><![CDATA[Tirzepatide research: what a 217,000-person comparison reported]]></title><description><![CDATA[Research summary. Everything below describes published research on tirzepatide as a compound. Nothing here is advice, and no outcome, benefit or dose is implied for any person. Products are supplied for laboratory research use only, not for human consumption. Tirzepatide is one of the most heavily studied research peptides in circulation right now. It is a dual receptor agonist, acting on both the GLP-1 and GIP receptors, two of the gut hormone pathways that sit at the centre of metabolic...]]></description><link>https://www.revexa.co.uk/post/tirzepatide-research-what-a-217-000-person-comparison-reported</link><guid isPermaLink="false">6a6fbd713e0c16484ff9e7ca</guid><pubDate>Sun, 02 Aug 2026 21:58:10 GMT</pubDate><dc:creator>Revexa | Research Peptides</dc:creator></item></channel></rss>